The Group navigated the challenges of H1 well and is on track to accelerate revenues in H2 as supply constraints ease and our marketing and product development initiatives stimulate greater demand. We remain on track to meet market expectations for full year financial performance, noting that the timing of certain orders in Q4 is dependent on the rate of recovery in those markets.
OPERATING AND FINANCIAL HIGHLIGHTS
H1 revenue growth impacted by lockdown in
Robust Prescription Medicine performance with revenues of
Free cash flow of
DEVELOPING OUR BUSINESS
Integration of ScarAway and US rights to Kelo-cote completed, with revenues in-line with expectations
Last remaining Nizoral marketing authorisations transferred from J&J to Alliance in
Several new complementary proprietary products launched, or planned to launch this year, including Kelo-cote Kids and Kelo-cote Scar Sheets in
ERP system successfully rolled out to further territories including
Scope 1 and 2 emissions target set to achieve net zero in 2030, with an interim reduction of 65% by 2025
Commenting on the results,
'The second half of 2022 has got off to an encouraging start as lockdowns and supply constraints have eased. We anticipate strong sales growth in H2 as our marketing campaigns yield benefits, we integrate our new distribution partners and launch new products to grow our market share. Our FY 22 expectation includes several large distributor orders in Q4 to meet increased demand, with the timing of these orders dependent on the rate of recovery in those markets. Our base business remains strong with further new product launches expected in 2023 to secure future growth.'
The performance of the Group is assessed using Alternative Performance Measures ('APMs'), which are measures that are not defined under IFRS but are used by management to monitor ongoing business performance against both shorter term budgets and forecasts and against the Group's longer term strategic plans. APMs are defined in note 17.
Contact:
Tel: + 44 (0)1249 466966
About Alliance
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the
(C) 2022 Electronic News Publishing, source